Medicamen Biotec

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE646B01010
  • NSEID: MEDICAMEQ
  • BSEID: 531146
INR
286.75
1.7 (0.6%)
BSENSE

Nov 20

BSE+NSE Vol: 5.37 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 770569,
    "name": "Medicamen Biotec",
    "stock_name": "Medicamen Biotec",
    "full_name": "Medicamen Biotech Ltd",
    "name_url": "stocks-analysis/medicamen-biotec",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "286.75",
    "chg": 1.7,
    "chgp": "0.6%",
    "dir": 1,
    "prev_price": "285.05",
    "mcapval": "399.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531146,
    "symbol": "MEDICAMEQ",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE646B01010",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "5.37 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/medicamen-biotec-770569-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Medicamen Biotech Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-ltd-hits-upper-circuit-amid-robust-buying-pressure-4263635",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MedicamenBiotec_stocks_hitting_upper_circuit_4263635.png",
        "date": "2026-11-16 10:00:25",
        "description": "At Rs 295.7, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Medicamen Biotech Ltd locked at its upper circuit of 5% on 16 Nov 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Medicamen Biotech Gains 7.79%: Downgrade and Lower Circuit Mark a Volatile Week",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-gains-779-downgrade-and-lower-circuit-mark-a-volatile-week-4255540",
        "imagepath": "",
        "date": "2026-11-07 16:00:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> Stock opens strong at Rs.264.25 (+3.42%)</p>\n                    <p><strong>3 Nov:</strong> Downgrade to Sell and hits lower circuit at Rs.247.10 (-5.00%)</p>\n                    <p><strong>4 Nov:</strong> Modest recovery to Rs.263.90 (+0.61%)</p>\n                    <p><strong>6 Nov:</strong> Strong rally closes week at Rs.275.40 (+4.95%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.255.50</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.275.40</div><div class=\"s..."
      },
      {
        "title": "Medicamen Biotech Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-ltd-hits-lower-circuit-amid-heavy-selling-pressure-4249537",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MedicamenBiotec_stocks_hitting_lower_circuit_4249537.png",
        "date": "2026-11-03 15:00:08",
        "description": "At Rs 247.1, sellers were still queuing — but there were no buyers willing to take the other side. Medicamen Biotech Ltd locked at its lower circuit of 5.0% on 03 Nov 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Medicamen Biotech Ltd is Rated Hold by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-hold-by-marketsmojo-4247338",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MedicamenBiotec_mojoScore_4247338.png",
        "date": "2026-11-02 10:10:02",
        "description": "Medicamen Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 October 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Medicamen Biotech Ltd Valuation Shifts to Fair Amidst Weak Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-ltd-valuation-shifts-to-fair-amidst-weak-returns-4241349",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/MedicamenBiotec_valuationdot_4241349.png",
        "date": "2026-10-28 08:00:45",
        "description": "Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in market perception. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios indicate a more cautious stance among investors amid subdued returns and sector headwinds."
      },
      {
        "title": "Medicamen Biotech Ltd Falls 11.42%: 4 Key Factors Driving the Weekly Decline",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-ltd-falls-1142-4-key-factors-driving-the-weekly-decline-4237352",
        "imagepath": "",
        "date": "2026-10-24 16:00:35",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>19 Oct:</strong> Stock opens at ₹272.65, down 4.82%</p>\n                    <p><strong>21 Oct:</strong> Golden Cross formation and valuation upgrade; stock closes at ₹263.65 (-3.30%)</p>\n                    <p><strong>22 Oct:</strong> Mild recovery with 1.23% gain to ₹266.90</p>\n                    <p><strong>23 Oct:</strong> Hits lower circuit, closes at ₹253.75 (-4.93%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹286.45</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">₹253.75</div>..."
      },
      {
        "title": "Medicamen Biotech Ltd Upgraded to Hold on Improved Technicals and Valuation",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/medicamen-biotech-ltd-upgraded-to-hold-on-improved-technicals-and-valuation-4233067",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/MedicamenBiotec_mojoScore_4233067.png",
        "date": "2026-10-22 08:21:48",
        "description": "Medicamen Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite ongoing challenges in financial performance and long-term returns, the company’s improved technical indicators and more attractive valuation relative to peers have prompted a reassessment of its market stance as of 21 October 2026."
      },
      {
        "title": "Golden Cross Forms in Medicamen Biotech Ltd — On a Day the Stock Fell 3.3%. What the Mixed Signals Mean",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-ltd-forms-golden-cross-indicating-potential-bullish-breakout-4232628",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/MedicamenBiotec_goldencross_4232628.png",
        "date": "2026-10-21 18:00:26",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Medicamen Biotech Ltd, signalling a golden cross on 21 Oct 2026. Yet, the stock declined 3.3% on the same day, and the broader technical indicators present a mixed picture, raising questions about the signal’s reliability."
      },
      {
        "title": "Medicamen Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/medicamen-biotech-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-4231224",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/MedicamenBiotec_valuationdot_4231224.png",
        "date": "2026-10-21 08:01:50",
        "description": "Medicamen Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite ongoing sector headwinds and a recent share price decline. This repositioning, driven by improved price-to-earnings and price-to-book value metrics relative to peers, offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 64,
    "sid": "770569",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/medicamen-biotech-770569"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Nov-2026",
      "details": "Announcement under Regulation 30 (LODR)- Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Financial Results - Quarter And Half Year Ended On September 30 2026",
      "datetime": "13-Nov-2026",
      "details": "Financial Results - Quarter and Half year ended on September 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On September 30 2026.",
      "datetime": "06-Nov-2026",
      "details": "Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 inter alia to consider and approve the unaudited financial results for the quarter and half year ended on September 30 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Medicamen Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Sep 26",
          "dt": "2026-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Nov-2026 | Source : BSE

Announcement under Regulation 30 (LODR)- Newspaper Publication

Financial Results - Quarter And Half Year Ended On September 30 2026

13-Nov-2026 | Source : BSE

Financial Results - Quarter and Half year ended on September 30 2026

Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On September 30 2026.

06-Nov-2026 | Source : BSE

Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 inter alia to consider and approve the unaudited financial results for the quarter and half year ended on September 30 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Medicamen Biotech Ltd has declared 10% dividend, ex-date: 18 Sep 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available